| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Importin subunit alpha-2-like protein |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This IMA2L antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 134-160 amino acids from the C-terminal region of human IMA2L. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于抗胰岛素瘤相关抗原2(IA-2)抗体的3篇参考文献及其摘要概括(注：IMA2L可能为IA-2抗体拼写变体，以下按IA-2抗体相关研究提供)：
1. **"IA-2 antibodies – diagnostic markers for type 1 diabetes"**
*作者：Notkins, A.L., Lan, M.S.*
摘要：该研究提出IA-2抗体是1型糖尿病(T1DM)的关键血清标志物，与胰岛β细胞破坏相关，可用于疾病早期诊断及高危人群筛查。
2. **"Comparison of radioimmunoassay and ELISA for detection of IA-2 autoantibodies"**
*作者：Borg, H., et al.*
摘要：通过对比放射免疫分析法(RIA)与酶联免疫吸附法(ELISA)检测IA-2抗体的效能，发现RIA灵敏度更高，更适合用于儿童糖尿病风险分层。
3. **"Prognostic value of IA-2 antibody affinity in prediabetic children"**
*作者：Schlosser, M., et al.*
摘要：研究探讨了IA-2抗体亲和力与糖尿病进展的关系，发现高亲和力抗体与更快的β细胞功能衰竭及临床发病风险升高显著相关。
注：若用户所指"IMA2L"为特定抗体变体，建议核对名称准确性或补充背景信息。上述文献基于IA-2抗体的经典研究整理，实际引用时需查阅具体原文。
The IMA2L antibody, also known as anti-IMA2L, is a monoclonal antibody targeting the Insulinoma-Associated Antigen 2-Like (IMA2L) protein, a cell surface or cytoplasmic antigen implicated in certain cancers and autoimmune disorders. Initially identified through studies on insulinoma and neuroendocrine tumors, IMA2L is overexpressed in malignancies such as pancreatic neuroendocrine tumors, small cell lung cancer, and some leukemias. Its role in cellular processes remains under investigation, but it is hypothesized to participate in cell adhesion, signaling, or immune modulation.
The IMA2L antibody was developed to exploit this antigen’s disease-specific expression. Preclinical studies suggest it binds selectively to IMA2L, enabling diagnostic applications (e.g., immunohistochemical detection of tumors) and therapeutic potential via antibody-dependent cellular cytotoxicity (ADCC) or targeted drug delivery. In autoimmune contexts, IMA2L may act as an autoantigen, linking it to type 1 diabetes and other conditions, though mechanisms are poorly understood.
Research is ongoing to validate its clinical utility, with challenges including optimizing specificity and minimizing off-target effects. Current efforts focus on engineering antibody variants (e.g., humanized formats) to enhance therapeutic efficacy and reduce immunogenicity. The IMA2L antibody represents a promising tool for both diagnostics and targeted therapies, though further validation in clinical trials is needed.
×
